Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00353587 | Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin | PHASE2 | COMPLETED | 396 | — | — | May 1, 2006 | Nov 1, 2007 | May 1, 2015 | 67 | United States, Argentina +2 |
| Arm | Type | Description |
|---|---|---|
| MBX-102 200 mg | EXPERIMENTAL | MBX-102 200 mg once daily for 16 weeks |
| MBX-102 400 mg | EXPERIMENTAL | MBX-102 400 mg once daily for 16 weeks |
| MBX-102 600 mg | EXPERIMENTAL | MBX-102 600 mg once daily for 16 weeks |
| Sugar Pill | PLACEBO_COMPARATOR | Placebo comparator once daily for 16 weeks |
| Actos | ACTIVE_COMPARATOR | Actos 30 mg once daily for 16 weeks |
| Name | Type | Description |
|---|---|---|
| MBX-102 | DRUG | MBX-102 200 mg once daily for 16 weeks |
| Placebo | DRUG | MBX-102 Placebo once daily for 16 weeks |
| Actos | DRUG | Actos 30 mg once daily for 16 weeks |
Inclusion Criteria: * Type 2 diabetes (as described by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus24) treated with insulin alone (a stable dose of long and/or intermediate-acting insulin or pre-mixed insulin e.g., "70/30") ≥ 30 units/day for at least 3 months, but ...